Last reviewed · How we verify
D326 and D337 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
D326 and D337 (D326 and D337) — Chong Kun Dang Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| D326 and D337 TARGET | D326 and D337 | Chong Kun Dang Pharmaceutical | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- D326 and D337 CI watch — RSS
- D326 and D337 CI watch — Atom
- D326 and D337 CI watch — JSON
- D326 and D337 alone — RSS
Cite this brief
Drug Landscape (2026). D326 and D337 — Competitive Intelligence Brief. https://druglandscape.com/ci/d326-and-d337. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab